SCHEMBL515979

SCHEMBL515979

Cc1cccc(C)c1OC(C)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN4A P35499 7/20 0.45
CYP2D6 P10635 3/20 0.45
LMNA P02545 3/20 0.45
SCN1A P35498 2/20 0.45
SCN5A Q14524 2/20 0.45
SCN9A Q15858 2/20 0.45
TSHR P16473 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
NFKB1 P19838 2/20 0.45
SCN8A Q9UQD0 2/20 0.45
CYP2C9 P11712 1/20 0.45
KCNK3 O14649 1/20 0.45
CACNA1F O60840 1/20 0.45
KCNK2 O95069 1/20 0.45
GBA1 P04062 1/20 0.45
MAOA P21397 1/20 0.45
HTR2A P28223 1/20 0.45
SLC6A4 P31645 1/20 0.45
HTR2B P41595 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18152139 0.87 TRPA1 (0.45) SCN4ACYP2D6LMNASCN1ASCN5A
SCHEMBL10359831 0.86 KDM4E (0.42) SCN4ACYP2D6LMNASCN1ASCN5A
SCHEMBL4082320 0.82 SCN4A (0.42) SCN4ACYP2D6LMNASCN1ASCN5A
SCHEMBL104735 0.80 SCN4A (0.48) SCN4ACYP2D6LMNASCN1ASCN5A
SCHEMBL11580891 0.77 SCN4A (0.45) SCN4ACYP2D6LMNASCN1ASCN5A
SCHEMBL23880668 0.76 SCN4A (0.45) SCN4ACYP2D6LMNASCN1ASCN5A
SCHEMBL11745605 0.76 SCN4A (0.45) SCN4ACYP2D6LMNASCN1ASCN5A
SCHEMBL23804880 0.76 SCN4A (0.45) SCN4ACYP2D6LMNASCN1ASCN5A
SCHEMBL9201474 0.76 SCN4A (0.55) SCN4ACYP2D6LMNASCN1ASCN5A
SCHEMBL3398522 0.76 MAPT (0.39) LMNASLC6A4ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111465589-B Compound having fluorene skeleton and method for producing same 帝人株式会社 2024-01-05 CN disclosed
US-11339249-B2 Compound having fluorene skeleton, and method for manufacturing same TEIJIN LIMITED (JP) 2022-05-24 US disclosed
EP-3747856-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME Teijin Limited (JP) 2020-12-09 EP disclosed
US-20200354517-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME TEIJIN LIMITED (JP) 2020-11-12 US disclosed
CN-111465589-A Compound having fluorene skeleton and method for producing same 帝人株式会社 2020-07-28 CN disclosed
WO-2020085222-A1 CRYSTAL OF COMPOUND HAVING FLUORENE SKELETON AND METHOD FOR PRODUCING SAME 帝人株式会社 2020-04-30 WO disclosed
WO-2019151264-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME 帝人株式会社 2019-08-08 WO disclosed
CN-102388012-B Method for producing fluorene derivative TAOKA CHEMICAL Co.,Ltd. (JP) 2014-10-15 CN disclosed
US-8841491-B2 Method for producing fluorene derivative TAOKA CHEMICAL CO., LTD. (JP) 2014-09-23 US disclosed
EP-2420485-A1 METHOD FOR PRODUCING FLUORENE DERIVATIVE Taoka Chemical Co., Ltd. (JP) 2012-02-22 EP disclosed
EP-0391942-A1 PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1990-10-17 EP disclosed
US-4935540-A OXIDIZING ARYLOXYETHANOL IN PRESENCE OF PALLADIUM AND THALLIU M ON CARBON CATALYST, ACIDIFYING EASTMAN CHEMICAL COMPANY 1990-06-19 US disclosed
WO-1989003378-A1 PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID EASTMAN KODAK COMPANY (US) 1989-04-20 WO disclosed
US-4804777-A OXIDATION OF ARYLOXYETHANOL USING PALLADIUM, SILVER, CARBON CATALYST EASTMAN KODAK COMPANY (US) 1989-02-14 US disclosed
US-4780462-A Antihypertensive 1,5-benzothiazepine derivatives and compositions thereof Kotokuki Seiya Kau Co., Ltd. (JP) 1988-10-25 US disclosed
EP-0011793-B1 PROCESS FOR PREPARING ARYLOXYACETIC ACIDS BAYER AG (DE) 1981-09-02 EP disclosed
US-4244731-A APPLYING A CARBOXY DERIVATIVE OF A 2,6-DIMETHYLPHENOXY COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1981-01-13 US disclosed
US-4238625-A ACTIVATORS OF LEAD AND/OR BISMUTH AND/OR THEIR COMPOUNDS FOR OXIDATION WITH PLATINUM OR PALLADIUM CATALYST BAYER AKTIENGESELLSCHAFT (DE) 1980-12-09 US disclosed
EP-0011793-A1 Process for preparing aryloxyacetic acids BAYER AG (DE) 1980-06-11 EP disclosed
US-4082808-A ANTIOXIDANTS, INTERMEDIATES FOR POLYESTERS, POLYCARBONATES, EPOXY RESINS GENERAL ELECTRIC COMPANY (US) 1978-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200354517-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME RFT1, AFF1, RER1 SCN4A 3748/4885CYP2D6 3183/4885LMNA 1995/4885
US-11339249-B2 Compound having fluorene skeleton, and method for manufacturing same RFT1, AFF1, RER1 SCN4A 3748/4885CYP2D6 3183/4885LMNA 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.